Nonstatin Therapy Decisions

Panelists discuss how clinicians decide when to introduce nonstatin low-density lipoprotein (LDL)–lowering agents such as ezetimibe or PCSK9 inhibitors. The choice depends on residual LDL levels, patient risk category, and prior therapy response.

They emphasize early combination therapy for high-risk patients, noting that waiting for repeated therapy failures delays optimal outcomes.

Panelists stress that structured treatment algorithms and patient follow-up can ensure timely intensification and reduce long-term cardiovascular risk.